thalidomide has been researched along with Parkinsonian Disorders in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide is a sedative with unique pharmacological properties; studies on epilepsy and brain ischemia have shown intense neuroprotective effects." | 1.42 | Neuroprotective effect of thalidomide on MPTP-induced toxicity. ( Escamilla-Ramírez, A; Garcia, E; Osorio-Rico, L; Palencia, G; Sotelo, J; Trejo-Solís, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palencia, G | 1 |
| Garcia, E | 1 |
| Osorio-Rico, L | 1 |
| Trejo-Solís, C | 1 |
| Escamilla-Ramírez, A | 1 |
| Sotelo, J | 1 |
| LAIDLAW, J | 1 |
| CATLING, J | 1 |
2 other studies available for thalidomide and Parkinsonian Disorders
| Article | Year |
|---|---|
Neuroprotective effect of thalidomide on MPTP-induced toxicity.
Topics: Animals; Corpus Striatum; Dopamine; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Neuroprotecti | 2015 |
AN E.E.G. ASSESSMENT OF ENCEPHALOPATHY IN PARKINSONISM.
Topics: Brain Diseases; Drug Therapy; Electroencephalography; Geriatrics; Parkinsonian Disorders; Surgical P | 1964 |